ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1023

Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases
Abstract Number: 1024

Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
Abstract Number: 1025

Association Between Rural-Urban Clinics and the Management of Adult Rheumatoid Arthritis in the United States
Abstract Number: 1026

Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends.
Abstract Number: 1027

GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 1028

Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
Abstract Number: 1029

Cervical cancer screening rates in Korean women of childbearing age with systemic lupus erythematosus
Abstract Number: 1030

Predictors of Incident Atrial Fibrillation in Rheumatoid Arthritis Patients: A Population Based Cohort Study
Abstract Number: 1031

Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Abstract Number: 1032

Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Abstract Number: 1033

Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
Abstract Number: 1034

Healthy Dietary Patterns and Risk of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 1035

Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center
Abstract Number: 1036

Factors Associated With Long-term Remission After Drug Discontinuation In IgG4-related Disease: A 3-Year Rule
Abstract Number: 1037

Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].